Full Text View
Tabular View
Study Results
Related Studies
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
This study has been completed.
Study NCT00284518   Information provided by Allergan

First Received on January 31, 2006.   Last Updated on November 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Benign Prostatic Hyperplasia
Additional conditions recognized in this trial
Hyperplasia
Prostatic Hyperplasia
More general conditions related to this trial
Genital Diseases, Male
Pathologic Processes
Prostatic Diseases
Interventions listed in this trial
botulinum toxin Type A
normal saline
Additional drug interventions recognized in this trial
Botulinum Toxins
Botulinum Toxins, Type A
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Central Nervous System Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Allergan


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services